Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kohei Nakachi

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Clinical Journal of Gastroenterology|June 11, 2020
Double small bowel cancers leading to the diagnosis of Lynch syndrome with germline MSH6 mutation in an elderly patientSae Ohwada, Kentaro Yamashita, Tomoe Kazama, et al.
Oncology|November 11, 2010
Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 casesEiichiro Suzuki, Junji Furuse, Masafumi Ikeda, et al.
International Journal of Clinical Oncology|April 30, 2018
Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancerKohei Nakachi, Masaru Konishi, Masafumi Ikeda, et al.
Japanese Journal of Clinical Oncology|January 6, 2010
Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreasSatoru Iwasa, Chigusa Morizane, Takuji Okusaka, et al.
Japanese Journal of Clinical Oncology|April 5, 2011
Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolizationSatoru Iwasa, Masafumi Ikeda, Takuji Okusaka, et al.
Japanese Journal of Clinical Oncology|August 5, 2006
Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancerJunji Furuse, Takuji Okusaka, Akihiro Funakoshi, et al.
International Journal of Radiation Oncology, Biology, Physics|July 8, 2010
Dose-volume histogram analysis of the safety of proton beam therapy for unresectable hepatocellular carcinomaMitsuhiko Kawashima, Ryosuke Kohno, Kohei Nakachi, et al.
Cancer Chemotherapy and Pharmacology|November 29, 2011
Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patientsChigusa Morizane, Takuji Okusaka, Hideki Ueno, et al.
Cancer Science|December 24, 2010
Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancerTakuji Okusaka, Junji Furuse, Akihiro Funakoshi, et al.
Experimental and Therapeutic Medicine|December 15, 2018
Rare case of idiopathic sclerosing cholangitis, which was difficult to distinguish from cholangiocarcinoma: A case reportShunsuke Shichi, Takahiro Einama, Mayu Suzuki, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Clinical Journal of Gastroenterology|June 11, 2020
Double small bowel cancers leading to the diagnosis of Lynch syndrome with germline MSH6 mutation in an elderly patientSae Ohwada, Kentaro Yamashita, Tomoe Kazama, et al.
Oncology|November 11, 2010
Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 casesEiichiro Suzuki, Junji Furuse, Masafumi Ikeda, et al.
International Journal of Clinical Oncology|April 30, 2018
Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancerKohei Nakachi, Masaru Konishi, Masafumi Ikeda, et al.
Japanese Journal of Clinical Oncology|January 6, 2010
Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreasSatoru Iwasa, Chigusa Morizane, Takuji Okusaka, et al.
Japanese Journal of Clinical Oncology|April 5, 2011
Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolizationSatoru Iwasa, Masafumi Ikeda, Takuji Okusaka, et al.
Japanese Journal of Clinical Oncology|August 5, 2006
Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancerJunji Furuse, Takuji Okusaka, Akihiro Funakoshi, et al.
International Journal of Radiation Oncology, Biology, Physics|July 8, 2010
Dose-volume histogram analysis of the safety of proton beam therapy for unresectable hepatocellular carcinomaMitsuhiko Kawashima, Ryosuke Kohno, Kohei Nakachi, et al.
Cancer Chemotherapy and Pharmacology|November 29, 2011
Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patientsChigusa Morizane, Takuji Okusaka, Hideki Ueno, et al.
Cancer Science|December 24, 2010
Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancerTakuji Okusaka, Junji Furuse, Akihiro Funakoshi, et al.
Experimental and Therapeutic Medicine|December 15, 2018
Rare case of idiopathic sclerosing cholangitis, which was difficult to distinguish from cholangiocarcinoma: A case reportShunsuke Shichi, Takahiro Einama, Mayu Suzuki, et al.
Pageof 5